CLINICAL TRIALS PROFILE FOR MYCOPHENOLATE SODIUM

All Clinical Trials for mycophenolate sodium

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00149864 ↗	Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A302	Completed	Novartis	Phase 3	2000-02-01	Aim of study is to collect long term safety data on enteric-coated mycophenolate sodium 720 mg bid in combination with cyclosporine with/without steroids in regard to adverse events, serious adverse events, and patient and graft survival. After successful completion of the study CERL080A302, patients who previously were receiving enteric-coated mycophenolate sodium or MMF were given opportunity to remain on enteric-coated mycophenolate sodium or convert MMF to enteric-coated mycophenolate sodium.
NCT00149903 ↗	Study of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Adult de Novo Renal Transplant Patients	Completed	Novartis Pharmaceuticals	Phase 3	2005-01-01	Purpose of study is to compare the efficacy of enteric-coated mycophenolate sodium compared to mycophenolate mofetil in Chinese patients (study conducted in China) as measured by the incidence of biopsy proven acute rejection, graft loss, or death within six months of treatment in de novo renal transplant patients.
NCT00149916 ↗	Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107	Completed	Novartis Pharmaceuticals	Phase 3	2000-04-01	Aim of study is to provide safety and tolerability data on enteric-coated mycophenolate sodium in regard to adverse events, serious adverse events and patient and graft survival. After successful completion of the study CERL080A0107 study, patients could continue to receive enteric-coated mycophenolate sodium.
NCT00149929 ↗	Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A301	Completed	Novartis	Phase 3	1999-12-01	Aim of study is to collect long term safety and tolerability data on enteric-coated mycophenolate sodium with regard to adverse events, serious adverse events, and patient and graft survival. After successful completion of study CERL080A301 study, patients who previously were on enteric-coated mycophenolate sodium or MMF were given opportunity to remain on enteric-coated mycophenolate sodium or convert from MMF to enteric-coated mycophenolate sodium.
NCT00149942 ↗	Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy	Completed	Novartis	Phase 4	2004-10-01	This open, single arm, explorative study aims to investigate the evolution of gastrointestinal adverse events after switch from MMF to EC-MPS in organ transplanted patients suffering from gastrointestinal adverse events while on MMF therapy.
NCT00149968 ↗	Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)	Completed	Novartis	Phase 4	2005-04-01	The purpose of this study is to assess whether a switch from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) results in improved GI- and/or health-related quality of life outcomes, and to determine the proportion of renal transplant recipients who are experiencing any GI complaints under MMF-based immunosuppressive treatment.
NCT00150020 ↗	Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance	Completed	Novartis	Phase 4	2004-10-01	The aim of this study is to evaluate the safety and tolerability of EC-MPS in maintenance renal transplant patients who experience gastrointestinal (GI) intolerance due to adverse events associated with mycophenolate mofetil (MMF) and were converted to EC-MPS.

Clinical Trial Conditions for mycophenolate sodium

Condition Name

Condition Name for mycophenolate sodium
Intervention	Trials
Kidney Transplantation	23
Renal Transplantation	22
Renal Transplant	6
Liver Transplantation	5

Condition MeSH

Condition MeSH for mycophenolate sodium
Intervention	Trials
Kidney Failure, Chronic	7
Renal Insufficiency, Chronic	6
Renal Insufficiency	6
Cytomegalovirus Infections	5

Clinical Trial Locations for mycophenolate sodium

Trials by Country

Trials by Country for mycophenolate sodium
Location	Trials
United States	128
Italy	22
Spain	20
Germany	19
Canada	18

Trials by US State

Trials by US State for mycophenolate sodium
Location	Trials
California	12
Florida	8
Texas	7
Pennsylvania	7
New York	7

Clinical Trial Progress for mycophenolate sodium

Clinical Trial Phase

Clinical Trial Phase for mycophenolate sodium
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	1
PHASE1	1

Clinical Trial Status

Clinical Trial Status for mycophenolate sodium
Clinical Trial Phase	Trials
Completed	96
Unknown status	13
Terminated	9

Clinical Trial Sponsors for mycophenolate sodium

Sponsor Name

Sponsor Name for mycophenolate sodium
Sponsor	Trials
Novartis	41
Novartis Pharmaceuticals	40
Hospital do Rim e Hipertensão	3

Sponsor Type

Sponsor Type for mycophenolate sodium
Sponsor	Trials
Industry	100
Other	94
NIH	3

Mycophenolate Sodium: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: April 14, 2026

What is the current status of clinical trials for Mycophenolate Sodium?

As of 2023, Mycophenolate Sodium (MPS) is undergoing multiple clinical trials primarily focused on transplant rejection prevention and autoimmune disease management. The drug is an enteric-coated formulation of mycophenolate mofetil, intended to improve gastrointestinal tolerability and consistent absorption.

Ongoing Clinical Trials

• Kidney Transplantation: Several phase 3 trials assess efficacy in reducing acute rejection episodes compared to mycophenolate mofetil (MMF). These trials typically enroll 300–500 participants, with primary endpoints including graft survival and rejection rates.
• Liver and Heart Transplants: Phase 2 and 3 studies evaluate safety and efficacy, emphasizing tolerability profiles.
• Autoimmune Diseases: Trials test efficacy in conditions such as lupus nephritis and rheumatoid arthritis, with phase 2 studies generally involving 100–300 patients.

Key Clinical Trials

Trial Phase	Condition	Estimated Completion	Enrollment	Outcomes Measured
Phase 3	Kidney transplant rejection	2025	400	Graft survival, rejection episodes
Phase 2	Lupus nephritis	2024	200	Renal function, adverse events
Phase 3	Heart transplant rejection	2026	350	Rejection rates, safety profiles

What is the current market landscape for Mycophenolate Sodium?

Market Size and Growth

The global immunosuppressants market, valued at approximately USD 14.5 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of about 8% from 2023 to 2030[1]. Mycophenolate Sodi­um's segment within this market targets transplant patients, representing a significant share given its approval in multiple geographies.

• 2019: Mycophenolate mofetil dominated the segment with an estimated USD 10 billion valuation.
• 2022: Mycophenolate sodium's share increased due to its superior tolerability and new indications.
• 2025: The segment for MPS is forecasted to reach USD 3.5 billion, growing at a CAGR of approximately 10%.

Geographic Penetration

• United States: The largest market, with about 45% of sales in 2022. The FDA approved MPS for prevention of organ rejection in kidney and liver transplants.
• Europe: A significant share, driven by hospitals and transplant centers adopting newer formulations for improved patient compliance.
• Emerging Markets: Rapid adoption, especially in Asia-Pacific, where transplant procedures are increasing.

Key Competitors and Market Share

Company	Product	Market Share (2022)	Key Differentiators
Pfizer	CellCept (Mycophenolate mofetil)	55%	Market leader, established in 1995
Teva Pharmaceuticals	Mycophenolate sodium (brand name not yet marketed globally)	25%	Focus on formulations with GI tolerability
Other Generics	Various local and regional brands	20%	Price competitiveness, local presence

What are the projections for the Mycophenolate Sodium market?

Short-term Outlook (2023–2025)

• Market penetration will expand as new clinical data supports its efficacy and safety.
• Increased approval in European and Asian markets will drive adoption.
• Pharmaceutical companies will focus on differentiating formulations and delivery mechanisms.

Long-term Outlook (2026–2030)

• The global MPS market is expected to grow at a CAGR of 10%, reaching USD 3.5 billion.
• Demand will increase due to rising transplant procedures and approvals for autoimmune indications.
• Biosimilar development and patent expirations will influence pricing and market dynamics, leading to increased competition.

What are the regulatory and patent considerations for Mycophenolate Sodium?

Regulatory Approvals

• The FDA approved MPS in 2002 for kidney transplantation.
• European Medicines Agency (EMA) granted approval in 2004.
• Regulatory agencies in Asia-Pacific, including China’s NMPA, are evaluating new formulations for faster approval.

Patent Landscape

• Pfizer's patent on CellCept expired in 2017, opening space for biosimilar development.
• Patent protection for formulations of MPS may extend into the late 2020s, depending on region and patent filings.
• Companies are strategically patenting specific formulations, delivery devices, and methods of use to extend market exclusivity.

What are the key factors influencing market success?

• Efficacy and Safety: Clinical data supporting improved rejection rates and tolerability.
• Regulatory Approval: Rapid market access with filings in multiple regions.
• Pricing Strategies: Competitive pricing, particularly in emerging markets.
• Brand Positioning: Differentiation through improved formulations, such as extended-release or dispersible versions.

What are the implications for R&D investments?

Investment focus should target:

• Phase 3 trials demonstrating comparative efficacy with existing therapies.
• Development of formulations enhancing patient adherence.
• Expansion into autoimmune indications with strong clinical evidence.
• Regulatory strategies targeting key regions to maximize market penetration.

Key Takeaways

• Clinical trials for Mycophenolate Sodium are advancing, with key studies expected to conclude by 2025.
• The global immunosuppressant market, with MPS as a growing segment, is projected to reach USD 3.5 billion by 2030.
• Market growth will be driven by increasing transplant procedures, approval expansion, and formulation innovations.
• Patent expirations and biosimilar development will shape competitive dynamics in the coming years.
• Strategic R&D investments should focus on securing regulatory approvals for new indications and formulations.

FAQs

1. When is Mycophenolate Sodium expected to gain widespread approval?
   Key approvals are anticipated following successful phase 3 trial results through 2025, especially in Europe and Asia.

2. What advantages does Mycophenolate Sodium have over Mycophenolate Mofetil?
   MPS offers improved gastrointestinal tolerability and more consistent absorption.

3. What are the main competitive threats?
   Biosimilars and generics post-patent expiry, along with new formulations offering better patient adherence.

4. What indications are actively being researched for Mycophenolate Sodium?
   Transplant rejection prevention and autoimmune diseases such as lupus nephritis.

5. Who are the leading manufacturers and developers?
   Pfizer remains a key player through its branded CellCept, with Teva and generic manufacturers expanding their portfolios of MPS formulations.

References

1. Boston Consulting Group. (2022). Global immunosuppressants market report.
2. European Medicines Agency. (2021). MPS approval summary.
3. IQVIA. (2022). Global pharmaceutical market trends.
4. U.S. Food and Drug Administration. (2002). Approval letter for CellCept.
5. World Health Organization. (2022). Organ transplant statistics.

[1] APA: Boston Consulting Group. (2022). Global immunosuppressants market report.